Cargando…
Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients
OBJECTIVE: To estimate the absolute treatment effect of statin therapy on major adverse cardiovascular events (MACE; myocardial infarction, stroke and vascular death) for the individual patient aged ≥70 years. METHODS: Prediction models for MACE were derived in patients aged ≥70 years with (n = 2550...
Autores principales: | Stam-Slob, Manon C., Visseren, Frank L. J., Wouter Jukema, J., van der Graaf, Yolanda, Poulter, Neil R., Gupta, Ajay, Sattar, Naveed, Macfarlane, Peter W., Kearney, Patricia M., de Craen, Anton J. M., Trompet, Stella |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226996/ https://www.ncbi.nlm.nih.gov/pubmed/27554244 http://dx.doi.org/10.1007/s00392-016-1023-8 |
Ejemplares similares
-
Cost‐Effectiveness of Intensifying Lipid‐Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients
por: Stam‐Slob, Manon C., et al.
Publicado: (2017) -
Long-Term Effects of Statin Treatment in Elderly People: Extended Follow-Up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)
por: Lloyd, Suzanne M., et al.
Publicado: (2013) -
Impact of a Patient’s Baseline Risk on the Relative Benefit and Harm of a Preventive Treatment Strategy: Applying Trial Results in Clinical Decision Making
por: de Vries, Tamar I., et al.
Publicado: (2021) -
Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses
por: Trompet, Stella, et al.
Publicado: (2011) -
The association of kidney function and cognitive decline in older patients at risk of cardiovascular disease: a longitudinal data analysis
por: Zijlstra, Laurien E., et al.
Publicado: (2020)